Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 7Completed 2Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Breast Neoplasms 10Neoplasms 5Neoplasm Metastasis 5Adenocarcinoma 3Stomach Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Meningeal Carcinomatosis 1HER2-positive Breast Cancer 1Gastrointestinal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 117Oxaliplatin 111Fluorouracil 100Capecitabine 90Docetaxel 69Leucovorin 60Irinotecan 57Paclitaxel 49S 1 (combination) 38pembrolizumab 35Trastuzumab 31Radiotherapy 25Bevacizumab 20Nivolumab 19Epirubicin 19titanium silicide 18Surgical Procedures, Operative 17Carboplatin 17Ramucirumab 16Cetuximab 15Gastrectomy 13apatinib 12Everolimus 12Gemcitabine 11Albumin-Bound Paclitaxel 10Neoadjuvant Therapy 8Folfox protocol 8Drug Therapy 8Chemotherapy, Adjuvant 8Radiation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Stomach Neoplasms × trastuzumab deruxtecan × Clear all
NCT04989816 2024-11-21

DG-06

AstraZeneca

Phase 2 Completed
95 enrolled 22 charts
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03368196 2022-11-03

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Daiichi Sankyo

Phase 1 Completed
12 enrolled 15 charts
BreastGastrointestinal

Adenocarcinoma, Breast Neoplasms, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡